Navigation Links
NHS Will Do Well to Curb Use Of Umbilical Cord Blood For Treatment of Cancers

should discourage commercial banking of umbilical cord blood. On the contrary, women should be motivated to donate to public// blood banks without the motive of financial gains.

Umbilical cord blood endowed with stem cells are beneficial in treating diseases like childhood leukemia. Bone marrow which is used for treating such diseases is sometimes replaced with cord blood, which is inexpensive and relatively easy to obtain. Also cord blood is not known to spark off any harmful immune response or rejection in the recipient.

For these reasons interest has been growing in banking cord blood as insurance against future disease, but this has worrying implications for NHS services and little chance of benefit, says Dr Leroy Edozien, a Consultant Obstetrician and Gynaecologist at St Mary's Hospital, Manchester.

Cord blood banks generally fall into two groups. Public banks collect cord blood which has been altruistically donated. The blood is used to treat unrelated recipients or is collected from families with a known genetic disease that is treatable by blood stem cell transplantation.

Since 1996, the NHS has been banking donated cord blood through designated public banks run by the National Blood Service and there is universal approval of the storage of this blood.

In contrast, commercial (private) banks operate collection and storage of a baby's cord blood for later use by that person or their siblings should they develop an illness. This 'just-in-case' collection has been criticised by numerous medical bodies and is not recommended.

Scientific arguments against commercial cord blood banking include the chances of the blood being used are very small, the alternatives such as bone marrow, and the speculative claims about how cord blood could be used to treat disease.

But, whatever the scientific merits or demerits, commercial blood banking also raises serious resource, legal, and ethical issues for NHS maternity units, warns the author.

Taking the arguments for and against into consideration, the balance is tilted strongly against NHS trusts collecting cord blood for commercial banking. It should therefore be NHS policy not to facilitate umbilical cord blood collection by its staff, he concludes.



Source-Eurekalert
'"/>




Related medicine news :

1. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
2. Umbilical Cord Blood Could Predict Childhood Allergies
3. A Novel System For Clinical Banking Of Umbilical Cord Blood
4. Delay Umbilical Cord Clamping in Pre Term Babies
5. Doctor Dissuades Mothers from Umbilical Cord Banking
6. Umbilical Cord Blood Industry Matures
7. Parents Bank Kids Umbilical Cord Blood
8. Umbilical Cord Blood Banking of Negligible Value: Experts
9. Delayed Cutting of Umbilical Cord Has Benefits
10. Recommendations for Treatment of Blood Pressue
11. Blood Cells Capable of Regenerating Liver
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: